Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lots for you today from the 2023 STAT Summit. Our podcast came live from the rollicking Boston affair, and we heard from plenty of the field’s top players. This includes Biogen CEO Chris Viehbacher, who spoke of how the company wants to move forward in a more disciplined fashion. We also talk about why Beam Therapeutics is cutting back so dramatically, and more.

Read the rest…